cyrilzakka/clinical-trials huggingface dataset:
Imaging the Dopamine Systems in Bulimia Nervosa

This study will use positron emission tomography imaging to investigate the dopamine systems in people with bulimia nervosa.


Eligibility Criteria:
Inclusion Criteria:

Participants with BN:

* Meets DSM-IV criteria for BN
* Sufficiently medically and psychiatrically stable to participate in research

Health Control Participants:

* No current or past psychiatric illness
* Between 80% and 120% of ideal body weight

Exclusion Criteria:

All participants:

* Current use of psychotropic medication such as anti psychotics or antidepressants
* Pregnant or breastfeeding
* history of substance abuse
* Significant medical illness
* High blood pressure (resting systolic blood pressure greater than 150mmHg and diastolic blood pressure greater that 90 mmHg)
* Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV
* Metal implants or paramagnetic objects contained within the body that may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to specified reference book guidelines
* Exposed to radiation in the workplace or has had a nuclear medicine procedure during the 1 year before study entry
* Previous adverse reaction to psycho stimulants
VOPITB a New Devices to Determine Peripheral Arterial Stiffness: Validation Study

Our group has developed a device called "Velocidad Onda de Pulso Indice Tobillo Brazo (VOPITB)" . In this device the oscillometric method is used for easily and accurately measure the pulse wave velocity PWV in the arms and legs separately, allowing new arterial stiffness indices to be studied (sum, difference, ratio, baPWV and CAVI). The aim of our study will be to validate the PWV measures by VOPITB with other references devices that measures arterial stiffness. Moreover we will perform a clinical study to assess the clinical utility of VOPITB.


Eligibility Criteria:
Inclusion Criteria:

* Subjects ≥ 18 years who agree to participate in the study and do not meet any of the exclusion criteria.

Exclusion Criteria:

* History of CVD (ischaemic heart disease, stroke or peripheral arterial disease)
* Atrial fibrillation or other cardiac rhythm disorders
* Pacemaker-dependent
* Impalpable arterial pulse at site of measurement
* Pregnancy
* Terminal condition
* Age under 18 years
Interval Versus Continuous Training on Functional Capacity and Quality of Life in Patients With Coronary Artery Disease

Exercise therapy increase functional capacity improving the morbidity and mortality of patients with cardiovascular disease. Moderate continuous training is the best established training modality for this patients. However, a body of evidence has begun to emerge demonstrating that high intensity interval training obtained better results in terms of morbidity and mortality.

The purpose of this randomized clinical trial was to determine the effect of two types of exercise training: moderate continuous training vs high interval training on functional capacity and quality of life as well as verify the safety in its application.

We included 72 patients with coronary artery disease by assigning one of the training modality for 8 weeks. We analyzed cyclo-ergo-spirometry data, aspect related to quality of life as well as a record of adverse events.


Eligibility Criteria:
Inclusion Criteria:

* Coronary heart Disease, with functional class II-III according to New York Heart Association classification system.
* At least 4 weeks from acute cardiac event, percutaneous or surgery revascularization.
* Optimized medical treatment in adequate doses ( betablockers, ACE inhibitors, ARA II, statins and antiplatelet drugs)
* Age \> 18 years old.
* Willing to participate and sign an informed consent form

Exclusion Criteria:

* Residual ischemia waiting for revascularization.
* Any cardiac event for the last 4 weeks
* Abnormal Ergometry with hemodynamic or clinically significant arrhythmias during the procedure.
* History of severe ventricular arrhythmia
* Uncontrolled glycaemia or blood pressure
* Moderate to severe Chronic Pulmonary Obstructive Disease
* Osteomuscular and/or mental disorder that hampers an adequate adherence to the intervention program
* Other vascular diseases: rheumatologic/ autoimmune disorders, thrombopathies, hemophilia.
* Active oncologic disease.
* Treatment with corticosteroids.
Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High Responders

This study aims to predefine the threshold FSH doses during the early follicular phases in low- dose step-up ovulation induction cycles used to treat anticipated high responders by monitoring total testosterone and androstenedione blood levels. The blood levels of total testosterone and androstenedione levels will be measured in patients at the starting day and at every control day when vaginal sonographic folliculometries and blood estradiol measurements are made. Hence, we are aiming to define an early monitoring parameter by which we will be able to define a follicular response to treatment before estradiol rise or apparently selected follicular growth.

50 patients with anticipated high ovarian response, who are being planned to be conventionally treated with low-dose step-up ovulation induction and intrauterine insemination will be analysed in this study. At every control day including the start day, blood samples taken for blood estradiol (and if required progesterone) measurements will be used to measure blood androstenedione and total testosterone levels, as well. Hence, we will have defined an early parameter for defining follicular response in the first 5-7 days of low-dose step-up ovulation induction. Low-dose step-up ovulation induction will be started at 50-75Units/day of rhFSH and the dose will be increased at not earlier than the 7th day at an increment of +37,5Units/day unless a response is observed ( which is at least a 10mm follicle, selected for growth). If more than 3 dominant follicles are selected, the cycle will be cancelled. Otherwise, when at least one follicle \>16mm is obtained, a 150Microgram sc. injection will be administered for ovulation trigger and intrauterine insemination made at the 34th-36th hours.

Eligibility Criteria:
Inclusion Criteria:

* Primary/Secondary infertile women; aged 20-35 years of age
* High ovarian response to ovulation induction anticipated.(Antral follicle count on the 3rd day of cycle\>10)
* Mild male factor or normal sperm parameters
* Normal anatomic findings with the HSG
* Eugonadotropic
* Normal blood prolactin and TSH levels

Exclusion Criteria:

* Amenorrheic women
* Women with Diabetes Mellitus
* Body Mass Index: \<22 or \>30
* Age\<20 or \>35 years old
* Hormonal abnormalities: regarding prolactin, TSH
* Hypo- or Hypergonadotropic women
* Additional medical or surgical disease
* Ovarian cysts
* Previous ovarian surgery
COVID-19 Volumetric Quantification on Computer Tomography Using Computer Aided Diagnostics

The aim of the study is to asses the influence of computer aided diagnostic to the process of lung affection quantification on computer tomography in COVID-19 confirmed patients.

The lung involvement of COVID-19 patients has been showed to be correlated to clinical outcomes and became part of the clinical practice. Even though various scores can be used, the affection estimation is usually done on computer tomography, using radiologists's estimation skills which is a highly subjective process.

Artificial intelligence is a known objective constant and therefore a potential radiologist complement. This trial aims at studying the effect of using a computer aided diagnostic software integrated in the normal clinical practice of radiologists from Timisoara County Emergency Hospital. It uses the AI-PROBE analysis setup, which turns off the CAD outputs for randomly chosen 50% the cases (control) and then compares the radiological reports for differences between the two arms.

Eligibility Criteria:
Inclusion Criteria:

* RT-PCR confirmed patients of COVID-19

Exclusion Criteria:

* 15 or lower
The Influence of Growth Factors (PDGF), Applied as Autologous Thrombocyte Concentrate, on Functional Recovery

The purpose of this study is to test the hypothesis that the application of PRP leads to faster wound healing, less wound healing disorders, less pain and faster functional recovery after subacromial surgery.

Subacromial surgery of the shoulder is performed often. It concerns space creating interventions (open and arthroscopic subacromial decompression) and rotator cuff surgery (open and arthroscopic). In this kind of surgery good wound healing and tissue recovery is of great importance to achieve optimal results. Wound healing disorders, pain and the formation of adhesions may negatively influence the postoperative course and lead to extended rehabilitation. This has an unfavourable influence on the personal well being of the patient and the possibility to return to labour. Especially in cuff surgery the course is strongly influenced by the healing of the attachment of the cuff to the bone. Besides the development of minimal invasive techniques, it's necessary to look for possibilities to decrease the morbidity of these procedures. Recent studies show that growth factors play a major role in wound healing. This concerns particularly TFG-B (transforming growth factor B) and PDGF (platelet derived growth factor) present in thrombocytes. They act as chemotactic agents for polymorphonuclear leucocytes, macrophages, fibroblasts and lymphocytes. Both growth factors stimulate the wound healing and cause improved angiogenesis and fibroplasia. They also play a role in wound retraction and remodelling. In animal-experimental models it is proved that the application of TGF-B and PDGF improves woundhealing and leads to better mechanical properties of the scar tissue. Faster and better wound healing and decreased development of adhesions after subacromial surgery can possibly be influenced favourably by using thrombocyte concentrate. In the treatment with autologous thrombocyte concentrate a thrombocyte rich concentrate is obtained by a centrifuging method (Gravitational Platelet System (GPS), Biomet, Warsaw USA) (platelet rich plasma or PRP), that can be applied in the operating field. The concentrate is harvest from the patients own blood, sampled during the procedure. At random the concentrated is applicated and both groups are compared postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years old
* Given informed consent
* Clinical indication for Arthroscopic Sub-acromial decompression, i.e.: Painful arc, pain at abduction, positive Hawkinstest Insufficient clinical improvement after (at least) 6 months of conservative treatment or Clinical indication for a arthroscopic cuff repair of a MRI-proven treatable rotator cuff tear.

Exclusion Criteria:

* Coagulopathy
* Thrombocytopenia
* Use of corticosteroids
* Diabetics Mellitus
* Omarthritis
* AC-arthrosis
* Cuff arthropathy
* Neurological deficit at the ipsi-lateral extremity
* (Wish for) Pregnancy
* VAS \<2 or VAS \>9
Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cm

Preoperative chemotherapy is often used for patients with colorectal cancer liver metastasis (CLM). Many small CLMs (\<=2cm) may disappear after chemotherapy, while most of these are still alive. Ultrasonography (US) is a common imaging modality for the intraoperative detection tumor. Sonazoid is new echo-contrast agent, which is more stable and sensitive for detecting of small tumor. Investigators initially this prospective study to compare the detection performance before and after using sonazoid.


Eligibility Criteria:
Inclusion Criteria:

* Pathology confirmed colorectal adenocarcinoma
* One or more liver metastases less than 2 cm
* Multidisciplinary team recommend to perform preoperative chemotherapy
* Have baseline EOB-MR before chemotherapy

Exclusion Criteria:

* Could not fulfill the criteria of no evidence of disease (NED) after hepatic resection/ablation/radiotherapy
* With other malignancies
Self-assessment of Olfactory Disorders for French Speaking Patients

Sense of smell disorders are common and are said to affect up to 20% of the general population. They are often disabling and have a real impact on the quality of life. Smell disorders are most often assessed using a visual analogue scale and more rarely with objective tests (Sniffing Stick Test). Many ENT units do not have these objective tests because they are time-consuming and are not covered by health insurance.

Some teams, such as that of Dr Thomas Hummel of the Carl Gustav Carus University Clinic in Dresden Germany, have developed self-assessment questionnaires for the sense of smell in order to improve the overall care of patients with olfactory disorders. Two of these self-questionnaires seem to us to be particularly relevant for use in everyday practice.

Since then, these questionnaires have already been validated in different languages (English, Chinese, Korean...), but have never been translated and validated in French. Translating and validating these questionnaires into French would make it possible to improve the management and follow-up of French patients with olfactory disorders and to assess the impact of loss of smell on their quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Patient \> 18 years old
* Patient affiliated to a sickness insurance social protection scheme, beneficiary or rightful claimant
* Patient who has not expressed his or her opposition to the collection and processing of his or her data for research purposes after the investigator has provided informed information.
* Patient presenting an olfactory dysfunction of any acquired aetiology that has been evolving for at least 3 months without total recovery (case group).
* Patient with no sense of smell problems followed up in ENT for another pathology that does not affect the sense of smell (control group).

Exclusion Criteria:

* Patient in an emergency or life-threatening situation
* Patient under judicial protection
* Patient under guardianship or trusteeship
* Inability to provide informed information to the patient (patient does not speak or understand French)
* Patient with congenital syndromic or non-syndromic congenital anosmia
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with acute lung injury,open label, controlled prospective study.

Every patient will maintain their standard treatment of acute lung injury, with maximum tolerated dosage without side effects.

The day of infusion will be considered day zero. From that moment, followup will be divided into 2,7,14 days.

Clinical results will be analyzed after completion of 14 days of followup.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Age between 35 and 70 y
* Acute onset within 7 days.
* Oxygenation index:200\<PaO2/FiO2≤300mmHg; alveolar-arterial oxygen differences:P(A-a)O2\>35mmHg
* Bilateral infiltrates on chest radiography
* No cardiac failure

Exclusion Criteria:

* Declined to sign informed consent
* Socially and mentally disabilities
* Malignant diseases
* Combined with severe infectious diseases
* Patients with positive blood tests for Hepatitis B or Hepatitis C or HIV or tuberculosis at the time of screening
* Pregnant or perinatal women
* Severe diseases of any major organs
Hearing Preservation and Electro-acoustic Stimulation With EVO® Electrode Lead and Zebra® Sound Processor

Some candidates to cochlear implantation can have residual low frequencies hearing. The EVO electrode lead has been specifically designed to preserve this residual hearing through surgery. It is then possible to provide the patient with a electro-acoustic stimulation (EAS) which combines both an acoustical stimulation for the preserved low frequency hearing and an electrical stimulation through the cochlear implant. The major aim of this study is to evaluate hearing preservation after implantation with the EVO electrode lead.

The secondary outcome is to evaluate the benefit of EAS stimulation provided by the Zebra speech processor.

Some candidates to cochlear implantation can have residual low frequencies hearing. The EVO electrode lead has been specifically designed to preserve this residual hearing through surgery. It is then possible to provide the patient with a electro-acoustic stimulation (EAS) which combines both an acoustical stimulation for the preserved low frequency hearing and an electrical stimulation through the cochlear implant. Literature showed the EAS stimulation can lead to better speech understanding, especially in noisy situation, and can provide important information about intonating or melodic contours, thus increasing sound quality and music perception.

Objectives The major aim of this study is to evaluate hearing preservation after implantation with the EVO electrode lead.

The secondary outcome is to evaluate the benefit of EAS stimulation provided by the Zebra speech processor.

Methods Unaided tonal audiograms are measured for cochlear implant candidates with low frequency residual hearing before and after cochlear implantation with the EVO electrode lead.

Aided tonal audiograms and speech intelligibility in quiet and in noise are measured after implantation with the three modes of stimulation (acoustic stimulation AS, electric stimulation ES, and electro-acoustic stimulation EAS).

Eligibility Criteria:
Inclusion Criteria:

* Agreement to participate
* Above 18 years old
* Candidate for cochlear implantation
* Residual hearing in low frequencies (auditory thresholds better than or equal to 70 dB up to 500 Hz
* Native or fluent French speaker

Exclusion Criteria:

* No affiliation to social security
* No agreement
* Vulnerable patient
The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular Carcinoma

The aim of this study was to evaluate the surgical decisions and prognosis of the radiomics and Watson artificial intelligence in patients with hepatocellular carcinoma.

Hepatectomy is an effective treatment for patients with hepatocellular carcinoma, but liver failure after hepatectomy may lead to increased postoperative mortality.Therefore, it is very important to make preoperative surgical decisions, evaluate the safety of the operation and identify which patients are likely to suffer from liver failure.Imaging omics is a newly emerging research method in recent years, which has great potential in cancer diagnosis and treatment, and can monitor treatment and predict the prognosis of patients, so as to better realize accurate diagnosis and treatment of diseases.The artificial intelligence platform developed by IBM Watson for Watson tumor treatment decisions can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.

Eligibility Criteria:
Inclusion Criteria:

1. 18 years≤ Age ≤80 years
2. Compling with the diagnosis criteria of complex hepatic carcinoma.
3. Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled
4. Preoperative liver function is Child - Pugh grade A or B.
5. The patients are volunteered for the study.

Exclusion Criteria:

1. Patients with mental illness.
2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.)
3. The patients refused to take part in the study.
4. There are other co-existed malignant tumors.
5. Benign liver diseases.
6. Indocyanine green allergy
ONO-4538 Study in Patients With Richter's Transformation

Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma (HL)-type Richter's transformation
* In the case of DLBCL-type Richter's transformation, refractory, intolerant or ineligible for treatment of DLBCL
* Patients with measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Expected to survive for 90 days or more

Exclusion Criteria:

* Serious complications
* Active multiple cancers
* Active central nervous system (CNS) disease
* History of allogeneic hematopoietic stem cell transplantation
TEP Versus Open Repair of Sportsman's Hernia

Sportsman's hernia causes chronic groin pain in physically active adults. Open hernia repair without mesh or laparoscopic technique with mesh have been advocated in the treatment of sportsman's hernia. The aim of this randomized study is to compare the effectiveness of open technique to laparoscopic technique for the treatment of Sportsman´s hernia. The hypothesis is that laparoscopic technique is less painfull than open surgery for repair of sportsman's hernia.

Sportsman's hernia is defined as a weakness or disruption of the posterior wall of the inguinal canal. Open hernia repair with or without mesh or laparoscopic techniques with mesh have been advocated in the treatment of sportsman's hernia and associated athletic pubalgia. The results of the operative treatment from single centers are reported to be good to excellent in between 70 - 90% of patients with the most promising results reported using an open minimal repair (OMR) technique. There are no randomized trials comparing open versus laparoscopic techniques regarding time for recovery and relief of pain. The aim of this randomized study is to compare the effectiveness of OMR technique in local or spinal anesthesia to endoscopic Total ExtraPeritoneal (TEP) technique in general anesthesia for the treatment of Sportsman´s hernia/athletic pubalgia. The primary endpoint is patient being free from intractable groin pain during sports activity or daily work four weeks after surgery.

Eligibility Criteria:
Inclusion Criteria:

* males/females professional or non-professional athletes
* age 18-50 years
* unilateral or bilateral groin pain lasting \> 6 weeks
* physical examination and MRI indicating sportsman's hernia
* pain above inguinal ligament in the deep inguinal ring
* grade I-II edema at pubic symphysis on MRI scan is allowed

Exclusion Criteria:

* patients not willing to participate
* inguinal or femoral hernia
* MRI reveals other major pathology
* former surgery to the actual groin
* allergy to polypropylene or other contra-indication to surgery